On Apr. 10, 2020, Terumo BCT and Marker Therapeutics announced the FDA issued an Emergency Use Authorization (EUA) for the use of Terumo BCTﾒs Spectra Optiaﾮ Apheresis System combined with Marker Therapeuticsﾒ D2000 Adsorption Cartridge to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19) admitted to the intensive care unit with confirmed or imminent respiratory failure to reduce pro-inflammatory cytokine levels.